Stephen Schmitz, MD, MPH is the Chief Medical Officer of ur24.  Originally training in family medicine, occupational medicine and public health, Dr. Schmitz has spent the last 25 years in drug safety, regulatory affairs and clinical trial development for leading biotech/pharma companies in the Boston area.  The elimination of catheter associated urinary tract infections (CAUTIs), a key distinguishing feature of TrueClr, is essential to patient safety and also decreasing hospital costs.  Other factors associated with TrueClr - enhanced patient comfort and dignity, cost savings, decreased nursing time, and use in hospitals, nursing homes, skilled nursing facilities and home - underscore the uniqueness of this product.  Dr. Schmitz will focus on connecting with health care professionals and setting up pilot studies in hospitals, leading to ongoing purchase of product.  The current urinary catheter choices for adults are invasive (i.e., indwelling catheter) or primitive.